Caption Management’s Biohaven Pharmaceutical Holding Company Ltd. BHVN Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2022
Q3
Sell
-20,400
Closed -$2.97M 1987
2022
Q2
$2.97M Sell
20,400
-154,500
-88% -$19.7M 0.04% 541
2022
Q1
$20.7M Sell
174,900
-67,400
-28% -$8.41M 0.25% 77
2021
Q4
$33.4M Buy
242,300
+217,300
+869% +$27.6M 0.37% 36
2021
Q3
$3.47M Sell
25,000
-65,000
-72% -$8.12M 0.04% 577
2021
Q2
$8.74M Buy
+90,000
New +$7.3M 0.11% 231
2021
Q1
Sell
-77,200
Closed -$6.62M 1538
2020
Q4
$6.62M Buy
77,200
+47,200
+157% +$4M 0.15% 180
2020
Q3
$1.95M Sell
30,000
-464,500
-94% -$30.4M 0.05% 433
2020
Q2
$36.2M Buy
494,500
+282,000
+133% +$15M 1.2% 4
2020
Q1
$7.23M Sell
212,500
-405,800
-66% -$18.6M 0.41% 50
2019
Q4
$33.7M Buy
618,300
+68,600
+12% +$3.4M 1.13% 8
2019
Q3
$22.9M Buy
549,700
+157,900
+40% +$6.67M 1.19% 7
2019
Q2
$17.2M Buy
+391,800
New +$22.1M 0.86% 13

Other funds holding BHVN

Caption Management's BHVN Position: Q2 2022 in Review

Caption Management sold out of Biohaven Pharmaceutical Holding Company Ltd. (BHVN) in Q2 2022, closing a stake of 91,500 shares — an estimated $11.7M sold.

Caption Management first reported a position in BHVN in Q1 2019 and held it in 12 quarters. The position peaked at $21.8M in Q4 2020. 329 funds tracked by Wall St. Rank hold BHVN as of Q2 2022.

  • Caption Management reported no remaining Biohaven Pharmaceutical Holding Company Ltd. position as of Q2 2022 after selling out during the quarter.
  • Caption Management sold 91,500 Biohaven Pharmaceutical Holding Company Ltd. shares in Q2 2022, an estimated $11.7M.
  • Caption Management first reported a position in Biohaven Pharmaceutical Holding Company Ltd. in Q1 2019 and held it in 12 quarters.
  • Caption Management's Biohaven Pharmaceutical Holding Company Ltd. position peaked at $21.8M in Q4 2020.
  • 329 funds tracked by Wall St. Rank held Biohaven Pharmaceutical Holding Company Ltd. as of Q2 2022.

Based on Caption Management's 13F filing for Q2 2022, filed 15 Aug 2022.